About 700 children in the U.S. are diagnosed annually with neuroblastoma, a common type of cancer that begins in the neck, chest, abdomen, pelvis or, most commonly, in the adrenal gland. Each year, 10 - 15 children with neuroblastoma treated in the Gill Center. Our multidisciplinary approach to develop treatment plans ensures that each child receives the best possible care.
The Neuroblastoma Program team is led by Tanya Watt, M.D., a pediatric oncologist with specialized interest in the care of children with neuroblastoma. The team also includes pediatric surgeons with expertise in removing these tumors, as well as pediatric pathologists and pediatric radiologists.
After a patient is admitted to Children’s, the team quickly biopsies the tumor to determine a diagnosis and then develops a treatment plan that relies typically on chemotherapy and surgery. Surgeons play a critical role in treating neuroblastoma, because some lower-stage tumors can be treated solely with surgical resection. Therefore, most of our pediatric surgeons are members of the Children’s Oncology Group. Oftentimes children with aggressive forms of neuroblastoma require stem cell transplants. In fact, the majority of autologous stem cell transplants performed at Children’s are patients with neuroblastoma. To help provide continuity of care for families of children with these tumors both during and after transplant, Dr. Watt also participates in the Gill Center’s Stem Cell Transplant Program.
- Program led by Dr. Tanya Watt, UT Southwestern’s Dedman Family Scholar in Clinical Care
- Features an experienced multidisciplinary team and coordination with the Gill Center’s Stem Cell Transplant Program
- Treats about 20 new patients annually
- Active participant in Children’s Oncology Group clinical trials